ERBB2 and cancer: Thedevice achieved 96% sensitivity and 100% specificity when used todetect CTCs in the blood of 79 cancer patients and 20 healthy controls.We demonstrate its postprocessing capacity with the identificationof potential responders to immune checkpoint inhibition (ICI) therapyand the detection of HER2 positive breast cancer.